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A B S T R A C T
Purpose
Evolving treatments, disease phenotypes, and biology, together with a changing drug development
environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical
trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups.
Methods
An international expert committee of prostate cancer clinical investigators (the Prostate Cancer
Clinical Trials Working Group 3 [PCWG3]) was reconvened and expanded and met in 2012-2015 to
formulate updated criteria on the basis of emerging trial data and validation studies of the Prostate
Cancer Clinical Trials Working Group 2 recommendations.
Results
PCWG3 recommends that baseline patient assessment include tumor histology, detailed records
of prior systemic treatments and responses, and a detailed reporting of disease subtypes based on
an anatomic pattern of metastatic spread. New recommendations for trial outcome measures
include the time to event end point of symptomatic skeletal events, as well as time to ﬁrst
metastasis and time to progression for trials in the nonmetastatic CRPC state. PCWG3 introduces
the concept of no longer clinically beneﬁting to underscore the distinction between ﬁrst evidence of
progression and the clinical need to terminate or change treatment, and the importance of doc-
umenting progression in existing lesions as distinct from the development of new lesions. Serial
biologic proﬁling using tumor samples frombiopsies, blood-based diagnostics, and/or imaging is also
recommended to gain insight into mechanisms of resistance and to identify predictive biomarkers
of sensitivity for use in prospective trials.
Conclusion
PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease
manifestations most likely to affect prognosis adversely for therapeutics tested in both non-
metastatic and metastatic CRPC populations. Consultation with regulatory authorities is recom-
mended if a trial is intended to seek support for drug approval.
J Clin Oncol 34:1402-1418. © 2016 by American Society of Clinical Oncology
INTRODUCTION
In 1999, the Prostate Cancer Clinical Trials
Working Group 1 issued recommendations for
standardizing prostate-speciﬁc antigen (PSA)
outcomes in phase II castration-resistant prostate
cancer (CRPC) trials.1 In 2008, when docetaxel
was the only drug proven to prolong survival
in metastatic CRPC (mCRPC),2,3 the successor
group, the Prostate Cancer Clinical Trials
Working Group 2 (PCWG2), outlined more
extensive principles of clinical trial conduct for
this disease.4 Incorporating the earlier recom-
mendations on the use of PSA measurements in
clinical investigations, PCWG2 applied a clinical
states framework in which trial objectives, design,
and outcomes were based on (1) early measures of
response that represented the control, relief, or
elimination of existing disease manifestations
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and (2) later time-to-event measures that represented the delay or
prevention of manifestations that may occur as disease progressed
(Appendix, online only).
The Prostate Cancer Clinical Trials Working Group 3
(PCWG3) is an international working group of clinical and trans-
lational experts in prostate cancer that convened in June 2012
and worked through February 2015 to update the recom-
mendations of PCWG2 in light of a changing therapeutic
landscape5-11 and advances in the understanding of disease biology.
The two chairs (H.I.S. and A.J.A.) developed an outline and convened
eight meetings that included many of the PCWG2 investigators and
20 additional investigators. A synthesized document was developed
and approved by all PCWG3 members. Key principles of trial
design and conduct from PCWG3 are shown in Tables 1–5 with
comparisons to the prior recommendations of PCWG2.
CONCEPTUALIZING THE DISEASE
The decision milestones in PCWG2 were based on disease
states deﬁned by the status of the primary tumor, the presence or
absence of distant disease on imaging (metastatic versus non-
metastatic), testosterone levels, and prior chemotherapy exposure.
PCWG3 presents a revised disease states model that, like its
predecessor, deﬁnes trial objectives on the basis of state-speciﬁc
clinical needs (Fig 1). Emphasis is placed on designing clinical trials
within a biomarker context, and focusing on how biomarkers can
be developed to predict outcome, guide management, and inﬂu-
ence clinical decision making. The revised model aligns with the
indications and uses of the currently approved drugs (see Appendix
Table A1, online only) and provides the framework for a decision
tree that closely follows contemporary clinical practice. Key
new recommendations of the decision tree include (1) dis-
tinguishing adenocarcinomas from other histologies including
pure small-cell carcinomas and variants with neuroendocrine
differentiation; (2) replacing the pre- versus postchemotherapy
distinction with a dynamic classiﬁcation that considers the lines of
therapy a patient has received independent of the mechanism of
action, the order in which they were administered, and the sen-
sitivity of the tumor to each; (3) designing dedicated trials for the
different CRPC phenotypes deﬁned by the pattern of spread; (4)
adding recommendations for trials in the nonmetastatic CRPC
(nmCRPC) state, formerly deﬁned as the rising PSA castrate state;
(5) emphasizing the importance of serial biologic proﬁling of the
disease using minimally invasive blood-based assays of tumor
material, imaging, or biopsy of a metastatic tumor site to identify
and target mechanisms of primary or adaptive resistance and to
better enable treatment selection to be based on disease biology; (6)
including clinically relevant time-to-event end points such as
symptomatic skeletal events (SSEs); and (7) with our increased
recognition of disease heterogeneity and emerging resistance,
focusing more on determining when a treatment should be dis-
continued when the patient is no longer clinically beneﬁting
(NLCB) rather than strictly at the ﬁrst evidence of progression.
OBJECTIVES
The objectives of the PCWG3 recommendations are to
identify subsets of patients for whom speciﬁc agents are most (or
least) appropriate, ensure that the determination of dose and
schedule for noncytotoxic treatments is mechanism speciﬁc, develop
intermediate end points to support regulatory submissions, assess
pre- and post-treatment disease biology, demonstrate the best use
of agents to maximize patient beneﬁt, and introduce the concept of
a new time-to-event measure, NLCB, as the indicator that a change
in therapy is necessary.
ELIGIBILITY FOR ENROLLMENT
Eligibility criteria deﬁne the population to be considered for
enrollment as one that has a high likelihood of demonstrating the
hypothesized effect of a treatment. The criteria may be based on
clinical features and laboratory measures that are prognostic,
predictive, or important from a safety perspective.
PATIENT DEMOGRAPHICS AND PATHOLOGY
Baseline Assessment
The baseline disease assessment recommendations of PCWG2
are expanded in PCWG3 (Table 2) to include histology; prior radi-
ation therapy; the timing and duration of, and (if available) response
to all prior systemic treatment(s); a standardized assessment of blood-
based biomarkers; patient-reported outcomes (PROs); imaging;
proﬁling disease by a repeat biopsy that also determines changes in
histology or through blood-based assays for molecular markers/
determinants of prognosis and drug sensitivity.
Prior Systemic Treatment
To better deﬁne and characterize a patient’s disease at the
time of trial enrollment and to explore potential favorable or un-
favorable interactions among therapies, PCWG3 recommends
recording all lines of therapy (represented as a single agent or
combination) in the order they were administered. Ideally,
reporting should include the start and stop dates, or at least the
duration, for each prior line of therapy; the dose and schedule of
the agent(s); the disease state in which it was administered; and the
type of progression (biochemical [ie, a rising PSA], radiographic,
and/or symptomatic). Response (resistant versus sensitive) should
be categorized on the basis of the post-therapy PSA or radiographic
change pattern for agents that reduce tumor burden. For example,
Appendix Fig A1 (online only) shows that post-therapy PSA
change patterns with agents that effect cell kill allow one to cat-
egorize response as resistant versus sensitive. Similar response
patterns to prior therapy that were based on other clinical bio-
markers such as imaging or pain may be considered and reported,
recognizing the challenges in obtaining such historical data.
The deﬁnition of a prior hormonal intervention is changed to
include only the addition of a hormonal therapy that had the intent of
treating the cancer. Assessing for a withdrawal response to an anti-
androgen is no longer considered an intervention and is not required,
but should be considered for 4 to 6 weeks for patients who have been
on long-term antiandrogen therapy with apparent beneﬁt. A response,
if it was observed on discontinuation, should be recorded.
Prior Radiation Treatment
Details of the dates, portals, number of fractions, dose per
fraction, and total administered dose by portal should be recorded
www.jco.org © 2016 by American Society of Clinical Oncology 1403
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for all courses of radiation therapy, including those directed at the
primary and metastatic site(s). Details of prior radioisotope
therapy should also be recorded.
Histology and Pathologic Subtype
To better inform future decision making, PCWG3 encourages
the direct biologic characterization of the tumor at the time a new
treatment is being considered by performing a biopsy of a
metastatic site or with blood-based diagnostics such as circulating
tumor cells (CTCs), circulating nucleic acids, or host factors (eg,
markers of bone turnover or immune function).
Although a number of prostate cancer histologic subtypes
have been described, only the pure small-cell phenotype is a
distinct entity that is diagnosed consistently.12,13 It represents less
than 1% of newly diagnosed prostate cancers but leads directly to
Table 1. Summary of Major Changes in PCWG3 Recommendations Compared With PCWG2
Clinical states model
1. Considers mCRPC in terms of number of lines of prior therapy rather than in relation to docetaxel treatment (ie, predocetaxel,
postdocetaxel; Fig 1)
2. Advocates recording the speciﬁc systemic approaches a patient has received in the order they were administered, including start and stop dates and response if
available
3. Distinguishes other histologies (ie, small-cell carcinomas) from adenocarcinomas
4. Emphasizes the importance of serial biologic proﬁling of the disease at the start of a new therapy and time of progression
Principles of trial conduct
1. Emphasizes discovering and qualifying post-treatment outcomes that reﬂect patient beneﬁt or can serve as surrogates of that beneﬁt for use in regulatory
submissions, to accelerate drug approvals
2. Highlights the distinction between the need to consistently report measures of progression in a trial v the clinical need to continue a particular therapy beyond
progression as long as the patient is beneﬁting from the treatment (Fig 3)
Eligibility for enrollment
1. Deﬁnes eligibility criteria using clinical and biologic parameters intended to homogenize the prognosis of the patients enrolled while enriching for tumor biomarker
proﬁles most likely to respond to a particular therapy
2. Encourages the use of testosterone assays that accurately measure levels in the 1-2 ng/dL range performed in a central laboratory
3. Assesses lymph node size on the basis of the short axis and eliminates the requirement for a lymph node to be $ 2 cm in size to be considered measurable
4. Encourages designing speciﬁc trials that are based on different clinical phenotypes deﬁned by the location and distribution of radiographic metastases for which
speciﬁc therapies have formal indications or exclusions
Treatment: deﬁning dose, schedule, and pharmacodynamic markers
1. Encourages the use of pharmacodynamic outcomemeasures that conﬁrm themechanism of action and determine a dose and schedule speciﬁc to the effect of a
particular agent on the malignant process
2. Places a greater focus on pharmacodynamic biomarkers that establish proof of mechanism and can also be used to determine dose and schedule on the basis of
biology (and safety) rather than safety alone
3. Advises that the post-treatment biomarker measurements used to assess antitumor activity be tailored to each agent’s mechanism of action and that these
measurements be performed at ﬁxed intervals (detailed in Table 4)
Baseline disease assessments
1. Expands baseline assessments to include tumor histology; the timing, duration, and response (if available) for all prior systemic treatments; a standardized assessment
of blood-based, PRO-based, and imaging-based biomarkers; and the molecular characterization of the tumor (detailed in Table 2)
2. Emphasizes molecular/biologic subtypes of CRPC in addition to the ﬁve clinical subtypes (deﬁned by extent and location of metastases)
3. Deﬁnes the type of progression at trial entry as PSA-only progression, radiographic progression by site of disease spread, or both; for radiographic progression,
records whether progression was caused by growth of existing lesions, appearance of new lesions, or both
Measuring outcomes and reporting: blood-based and molecular measures
1. When there are progressing lesions, recommends rebiopsy of the progressing metastatic site for histology and biomarker assessment
2. Suggests that PSA outcomes should be interpreted within the context of a drug’s mechanism of action, and the anticipated timing of a potential favorable/
unfavorable effect on PSA should be considered
3. Includes suggestions on how to deﬁne and report outcomes related to CTC enumeration (using CellSearch platform)
Measuring outcomes and reporting: PROs
1. Recognizes the importance of the patient perspective in prostate cancer clinical trials and the need to further optimize the assessment, collection, analysis, and
presentation of PRO data
2. Recommends measuring disease-related symptoms including pain intensity and interference, and physical functioning, using validated instruments
3. Recommends collecting patient-reported adverse events using the NCI’s PRO-CTCAE
Measuring outcomes and reporting: imaging and clinical measures
1. Reconsiders the mixed response designation, which may be a manifestation of disease heterogeneity
2. Advises recordingwhether disease progression represents growth of pre-existing lesions, development of new lesions, or both, and separately recordingwhether
progression is occurring in a single organ or disease site v multiple sites
3. Suggests that the ﬁrst post-treatment bone scan be used as the baseline scanwithwhich all future bone scans are compared (Fig 2); also emphasizes the notion of
response in bone, caused by the advent of novel bone-targeting agents
4. Advises recording the location of nodal disease (pelvic v extrapelvic) and visceral disease (lung/liver/adrenal/CNS) separately, because these sites have separate
prognostic implications
5. Also advises monitoring up to ﬁve individual lesions per site of spread (eg, nodes, lung, liver as separate sites) to address disease heterogeneity
6. Proposes new criteria to deﬁne the ﬁrst occurrence of metastatic disease in men with nmCRPC at enrollment
7. Highlights and deﬁnes the bone-related outcomes, SREs and SSEs, but suggests focusing on SSEs, which represent a more direct clinical beneﬁt to patients
8. Introduces the concept of treatment beyond progression where clinical beneﬁt by one or more disease manifestations is being observed, thus deﬁning an
objective of NLCB
Abbreviations: CRPC, castration-resistant prostate cancer; CTC, circulating tumor cell; mCRPC, metastatic castration-resistant prostate cancer; nmCRPC, non-
metastatic castration-resistant prostate cancer; NCI, National Cancer Institute; NLCB, no longer clinically beneﬁting; PRO, patient-reported outcome; PRO-CTCAE,
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; PSA, prostate-speciﬁc antigen; SRE, skeletal-related event; SSE,
symptomatic skeletal event.
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treatment with cytotoxic regimens similar to those used to treat
small-cell lung carcinomas of the lung and should thus be noted
speciﬁcally. Treatment-emergent histologic variants that con-
tain nonadenocarcinomatous elements are still being deﬁned
but are anticipated to differ from the de novo small-cell
phenotype.13
BLOOD-BASED BIOMARKERS
Baseline Measures
A baseline assessment of hematologic, hepatic, and renal
function is essential to assess prognosis, to predict response to
therapy, and for safety. Multivariable analyses suggest that
hemoglobin, alkaline phosphatase, albumin, and lactate dehy-
drogenase are established prognostic factors for survival14 and
should be included in all studies.
Testosterone. PCWG3 retains the deﬁnition of castrate as# 50
ng/dL of testosterone (or # 0.50 ng/mL or 1.73 nmol/L) but
encourages investigators to consider using ultrasensitive testosterone
assays with a sensitivity to 1 to 2 ng/dL when evaluating a drug
known or suspected to change androgen levels.
Bone biomarkers. Biochemical markers of osteoblast and
osteoclast activity are often reported but rarely used for eligibility
in most clinical trials.15 Although not required, they may be
measured as a prognostic and pharmacodynamic marker in certain
contexts.16
Immune function. Assays of immune function such as serum
cytokines, antibody response, T-cell subsets, function and antigen
speciﬁcity are increasingly included in trials. Most have not ach-
ieved the necessary level of analytical validity, with the exceptions
of the absolute lymphocyte count and neutrophil-to-lymphocyte
ratio, which are obtained from a complete blood count.17,18
PSA and other tumor markers. A rising PSA is typically the
ﬁrst sign of tumor regrowth, followed later by worsening of
disease by imaging and the development of clinical symptoms.19 PSA
should be assessed in all trials, and in particular for those with
PSA change as a primary end point, in a central laboratory to
minimize interassay variability. PCWG3 retains the PCWG2
criteria for PSA progression.5,6,10,11 For nmCRPC, PCWG3
advises recording PSA doubling times (PSADTs) and focusing
drug development efforts on patients with shorter times who
have the greatest risk of developing detectable metastatic disease
or symptoms, and dying of their cancers.20,21 The preferred
method for calculating PSADT is described in the Appendix.
Other markers in the blood, such as chromogranin A, neuron-
speciﬁc enolase, and carcinoembryonic antigen, have not been
validated in prospective studies (Table 2).
CTC number. The usefulness of CTC analyses at baseline and
during treatment is an area of active research. Although multiple
platforms are under development,22 CellSearch (Janssen Diag-
nostics, Raritan, NJ), which reports the number of cells captured
from whole blood with an EpCAM-positive immunomagnetic
ferroﬂuid, is the only US Food and Drug Administration–cleared
CTC assay at the present time.22 Baseline CTC count, reported as
favorable or unfavorable (, 5 versus $ 5 CTC/7.5 mL of blood,
respectively), has been shown to be an independent prognostic
factor for survival in CRPC both before and after treatment.22-24
Although the strengths and limitations of CTC enumeration as an
indicator of antitumor effects require further study, CTCs may be
considered for use as a screening end point for activity in patients
with unfavorable counts at baseline.25 CTCs can also serve as a
source of tissue for biologic proﬁling.26-28
PROs
PCWG3 recognizes the importance of patient-centered drug
development and reporting the patient experience on study.29 Pain
is the most established PRO in this population and is associated
with inferior survival and diminished quality of life.30-33 When
pain is an important component or primary end point of a study,
PCWG3 recommends a baseline assessment using serial mea-
surements, including pain intensity, pain interference with activ-
ities, and opiate intake, over several days before starting treatment,
using methods described by the US Food and Drug Admin-
istration.34 The average score over those days is used as the baseline
pain value.35 Pain questions using numerical rating scales (0 to 10)
can be used, eliciting worst pain intensity and interference over the
previous 24 hours.34
Physical functioning should also be assessed and can be
measured at baseline and during treatment using an estab-
lished multi-item questionnaire such as the physical function
measure of the European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire C30 or Patient-
Reported Outcomes Measurement Information System (PROMIS)
instruments. Collection of patient-reported adverse events should
be considered at baseline and during treatment using the National
Cancer Institute’s Patient-Reported Outcomes version of the
Common Terminology Criteria for Adverse Events (PRO-CTCAE).36
Clinically
Localized
Disease
Clinical
Metastases:
Noncastrate
mCRPC:
2nd Line
Rising
PSA
Noncastrate
nmCRPC
mCRPC:
1st Line
Castration-resistant
Noncastrate
mCRPC: 3rd Line, 4th Line, etc
mCRPC:
Line X
Fig 1. Prostate cancer clinical states model, a framework for patient treatment and drug development, updated for the Prostate Cancer Clinical Trials Working Group 3.
Combination therapy is considered one line of therapy. mCRPC, metastatic castration-resistant prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate
cancer; PSA, prostate-speciﬁc antigen.
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IMAGING
Imaging provides critical information on disease distribution,
prognosis, extent, biology, and host reaction to the tumor.
Baseline by Site of Disease
PCWG3 retains the PCWG2 recommendations with
modiﬁcations that include developing, recording, and vali-
dating measures of disease burden. Imaging of the chest, abdomen,
and pelvis using a contrast-enhanced computed tomography (CT)
scan with # 5-mm axial slices is advised for all patients. For those
intolerant of contrast, a cross-sectional magnetic resonance imaging
(MRI) scan of the abdomen and pelvis, with a noncontrast CTscan
of the chest, may be considered. In phase I and II trials, recognizing
that individual lesions may be biologically distinct, PCWG3 rec-
ommends reporting whether progression on entry was in the growth
of pre-existing lesions, the development of new lesions, or both.
PCWG3 advises following Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 for extraskeletal disease but recommends that
up to ﬁve lesions per site of metastatic spread (eg, lung, liver, lymph
nodes as separate sites) be recorded to address disease heterogeneity
and to track patterns of metastatic progression. Bone lesions should
be recorded separately (see Bone section on this page).
Prostate or prostate bed. Speciﬁc imaging of the prostate or
prostate bed is not required for every patient. If there is a question
of locally persistent or recurrent disease, a directed MRI of the
prostate or prostate bed and/or biopsy of the site is recommended.
Nodes or viscera. PCWG3 advises that nodal disease be meas-
uredintheshortaxisandrecordedbylocation:pelvicdiseaseshouldbe
classiﬁed as locoregional, and extrapelvic disease (retroperitoneal,
mediastinal, thoracic,orother)asmetastatic.Nodes$1.5cminthe
short axis are considered pathologic and measurable. As per
RECIST 1.1, lymph nodes that are $ 1.0 cm but less than
1.5 cm in the short axis may be pathologic and can be considered
nonmeasurable/nontarget lesions.37 Visceral disease in metastatic
patients should be designated separately as lung, liver, adrenal, or CNS
and is considered measurable if an individual lesion is $ 1 cm in its
longest dimension. Given that lungmetastases are relatively frequent in
mCRPC trials (7% prevalence), chest CT imaging is recommended.38
PCWG2 did not formally address trials in the nmCRPC
population, where the aim is to delay/prevent the development of
radiographically evident metastatic disease and death. To establish
nonmetastatic status, note that nodes less than 1.0 cm in the short
axis are nonpathologic; nodes 1.0 to less than 1.5 cm may be
considered pathologic, but with clinical discretion; and nodes
$ 1.5 cm are both pathologic andmeasurable. PCWG3 advises that
trial entry be based on PSADT, and that the same standard imaging
modalities (eg, bone scan, CT, and/or MRI) used to determine
eligibility be used for monitoring the patient receiving treatment.
Bone. The use of 99mTc-methylene diphosphonate radionuclide
bone scintigraphy as the standard for bone imaging is retained in
PCWG3, with the presence or absence of metastasis recorded ﬁrst. A
quantitative measure of disease burden, such as lesional number,39
the bone scan index,40,41 or lesion area,42 is also suggested, recognizing
that these measures require further analytical and prospective
clinical validation. Changes in lesions considered metastatic on
bone scintigraphy should be followed and assessed serially using a
bone scan assessment form (Appendix Fig A3, online only). Areas/
lesions on bone scintigraphy that are suggestive can be assessed further
with CT or MRI and followed separately, but such supplemental
imaging should not be used to establish indicator lesions for the
purposes of a trial.
Different modalities for imaging bone metastases can provide
different information for the same patient (Appendix Fig A2).
However, because of the lack of standards for reporting disease
presence or changes after treatment, positron emission tomog-
raphy imaging with sodium ﬂuoride, ﬂuorodeoxyglucose, choline,
or prostate-speciﬁc membrane antigen, bone marrow MRI (body
MRI), and othermodalities that are in use to image bone, should be
approached as new biomarkers subject to independent validation.
Neurologic. PCWG3 upholds the PCWG2 recommendation to
perform an MRI or CT of the brain for patients with small-cell/
neuroendocrine tumors and to maintain a low threshold for
performing an MRI of the base of the skull or spine to diagnose
and/or detect impending neurologic compromise. Routine imaging
of the brain for adenocarcinoma is not recommended.
Type of progression at entry into a trial. PCWG3 advises
recording whether progression was manifested by PSA alone, bone6
nodes by location, nodes by location only, or viscera (6 other sites),
and the proportion of patients who progress in each of these cate-
gories, because this is prognostic.5,6,10,11 PCWG3 also advises reporting
whether progression by imaging at study entry involved the growth or
enlargement of pre-existing lesions, the development of new lesions,
or both. The criteria for progression can be found in Table 3.
Clinical subtypes of CRPC that are based on pattern of
spread. The ﬁve clinical subtypes deﬁned in PCWG2 on the basis
of the pattern of spread in individual patients are retained with
modiﬁcations: (1) locally recurrent CRPC after radical prostatectomy
or persistent disease in the prostate or prostate bed after radiation ther-
apyonADT,withnoevidenceofmetastasesonimaging;(2)nonmetastatic
(nmCRPC):arisingPSAwithnodetectablediseaseintheprimarysite, in
lymphnodesbeyondthetruepelvisbyCT/MRI(lymphnodes#1.5cm
in the short axis in the pelvis are eligible), in bone by radionuclide bone
scan or CT, or in visceral organs; (3) nodal spread within the pelvis
(lymph nodes . 1.0 cm) and/or beyond the pelvis (specify) and no
evidence of bone or visceral disease43; (4) bone disease with or without
nodaldiseaseandnoevidenceofvisceral spread; (5)visceraldiseasewith
orwithout spread toother sites; includes spread to lung, liver, or adrenal
andCNSsites,eachreportedseparately. It is recommendedthatresearch
studies report the proportion of patients in each subtype. Stratiﬁcation
by pattern of metastatic spread is also encouraged.
MOLECULAR AND BIOLOGIC SUBTYPES
With the report of the CRPC genotypic landscape,44 PCWG3
strongly endorses incorporating detailed molecular assessments of
tumors into clinical trial strategies to better understand the disease
biology and to identify predictors of sensitivity to a speciﬁc therapy.
This requires the molecular characterization of an individual
patient’s tumor at the time treatment is considered. A proﬁle of the
primary tumor obtained at diagnosis may not be sufﬁciently infor-
mative for a castration-resistant metastatic site, because the biologic
drivers of growth and cell-surface targets can change as the disease
progresses through various treatments. Molecular biomarkers in
metastatic lesions can be assessed through a directed biopsy45,46 or
by using blood-based assays of CTCs or cell-free nucleic acids (RNA
www.jco.org © 2016 by American Society of Clinical Oncology 1407
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or DNA or proteins), recognizing that the biologic proﬁles of different
lesions and blood-based assays in the same patient may not be the
same. The number of tumor cells within a single metastatic site that
harbor a speciﬁc alterationmay also vary and, as such, simply detecting
its presence at a low frequency may not predict sensitivity.
ASSESSING PROGNOSIS
Prognosis indicates the likelihood that a patient or patient
group will develop a disease manifestation if left untreated. Pre-
dicted survival time is one measure estimated commonly by using
nomograms. Validated prognostic tools such as nomograms include
patient demographics and clinical measures to estimate outcomes
at a trial-based level as risk-stratiﬁcation tools.16,33,47-51 Adding
a measure of metastatic disease burden and type of radiographic
progression (new lesions versus growth of existing lesions) on the
basis of physician assessment or computer-based assessments
of bone or other disease sites may permit more reliable prog-
nostication.42,52 The incorporation of prognostic molecular bio-
markers is an active area of research.
INTERVENTION
In PCWG3, the term intervention includes both the therapy itself
and the post-treatment assessments to determine dose, schedule,
and antitumor effects. PCWG3 emphasizes the importance of
developing trials that provide the following information tailored to
the mechanism and postulated therapeutic target(s) of the agent:
population-speciﬁc pharmacokinetics in the castrate state, the use of
pharmacodynamic measures speciﬁc to the postulated effect of a
particular agent on the malignant process to conﬁrm or refute the
hypothesized mechanism of action, and the optimal timing to assess
the pharmacodynamic measures and to inform the determination of
the optimal dose and schedule to study in future trials. The optimal
time to assess for antitumor effects, which can be delayed for many
types of treatment including those that affect immune function,
should also be determined by assessing disease status at ﬁxed intervals.
MEASURING OUTCOMES AND REPORTING
PCWG3 reafﬁrms the recommendation to use control/relieve/
eliminate end points to assess antitumor effects of therapies that
are anticipated to kill tumor cells, particularly in early clinical
development. For therapies not expected to kill tumor cells,
delay/prevent end points should be used. PCWG3 discriminates
between activity-estimating end points in early-phase trials
(such as declines in PSA, changes in CTCs, and time to pro-
gression) where the objective is to demonstrate sufﬁcient
antitumor activity to justify further study, versus registration
trials for regulatory approval where clinical beneﬁt is the
objective. For instance, in early-phase trials, time to progression,
which censors deaths, may be used, whereas in registration
trials, progression-free survival, which includes deaths as events,
is preferred. The suitability of efﬁcacy end points to demonstrate
clinical beneﬁt is context dependent, and consultation with
regulatory authorities is strongly recommended when selecting
and deﬁning end points for a trial intended to support
drug approval.53 Although demonstrating overall survival may be
challenging as a primary end point, it is assumed that all trials will
continue to follow patients for survival and analyze and report
survival results, particularly in randomized clinical trials. PCWG3
also recommends that all therapies administered subsequent to the
intervention, including start and stop dates when available, be
recorded, until death. This is essential because the availability and
use of life-prolonging treatments post protocol may reduce the
ability to demonstrate the survival beneﬁt of an effective treatment.
On-treatment evaluations should include physical examinations,
symptom assessments, and laboratory studies to assess safety, with
appropriate attribution to the disease or therapy. Imaging should
include cross-sectional imaging of the chest, abdomen, and pelvis, as
well as bone scintigraphy, regardless of whether patients have
involvement of those sites at baseline. Imaging strategies restricted to
known sites of disease risk missing disease progression at new sites.
PCWG3 advises that disease assessments be performed at ﬁxed
intervals to better understand when antitumor effects occur
(Table 4). To minimize patient exposure to ineffective treatment,
and to better assess the timing of the antitumor effects of an agent
for which the optimal timing is not known, an 8- to 9-week
assessment interval for the ﬁrst 6 months and every 12 weeks
thereafter is advised. This recommendation is based on the ﬁndings
of several trials.5,10,54 The shorter interval also helps clarify bone
scan ﬂare (the development of new lesions on a ﬁrst follow-up scan
that may actually represent a favorable response to treatment).
Using the shorter interval will also inform the optimal assessment
interval in subsequent trials, particularly important for biologic
therapies whose antitumor effects may be delayed. Notable is that
the applicability of the immune-modiﬁed RECIST criteria to
prostate cancer has not been established, in particular, whether an
early increase in the size of a nodal or visceral lesion represents the
recruitment of immune effector cells or tumor growth.55 It is also
noteworthy that neither the RECIST criteria nor the immune-
modiﬁed RECIST criteria address changes in osseous disease.
APPLYING THE CONTROL/RELIEVE/ELIMINATE
VERSUS DELAY/PREVENT FRAMEWORK
PCWG3 retains the recommendation to report outcomes by
manifestation (eg, host or tumor biomarkers, symptoms, site of
spread) and not to report grouped categorizations of response such
as complete response, partial response, or progression on the basis
of multiple manifestations. In patients who show evidence of beneﬁt,
PCWG3 advises continuing therapy in the case of an isolated PSA rise
after an initial decline until radiographic or clinical progression is
manifest. Table 5 describes the updated PCWG3 recommendations
for reporting outcomes by disease manifestation. Of particular note is
the use of the 212 rule to distinguish ﬂare from true progression in
patients with osseous disease at baseline (Fig 2).4,6 Also recommended
are reporting the proportion of patients who have not progressed at
ﬁxed time intervals (eg, 6 or 12 months) and reporting separately the
time receiving treatment.
RADIOGRAPHIC PROGRESSION-FREE SURVIVAL
Radiographic progression-free survival (rPFS) is the time
interval from random assignment to the date when the ﬁrst site
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of disease is found to progress (using a manifestation-speciﬁc
deﬁnition of progression), or death, whichever occurs ﬁrst. To
better understand the effect of therapy on an individual site of
disease, PCWG3 advises the date of progression in all speciﬁc sites
be reported independently whether it is bone, nodes (pelvic or
extrapelvic), visceral (lung, liver, adrenal, or CNS), or other.
Reporting the proportion of patients who remain radiographic
progression free at ﬁxed time points (eg, 6 and 12 months) is also
advised.
PCWG3 also emphasizes the importance of analytically and
clinically validating the deﬁnitions of progression for each site of
disease, as was performed for the bone scan progression end point
proposed in PCWG2 that became part of the rPFS deﬁnition in the
phase III registration trials of abiraterone (NCT00887198), enzalu-
tamide (NCT01212991), and orteronel (NCT01193244). Noteworthy
is that in all three trials, the local radiology interpretations were highly
concordant with the centralized interpretation. The association
between rPFS and overall survival is still being investigated, but an
association was demonstrated in at least one of these trials.56
SKELETAL-RELATED EVENTS AND SYMPTOMATIC
SKELETAL EVENTS
Delay/Prevent
PCWG2 did not consider skeletal-related events (SREs), which
include asymptomatic nonclinical fractures ascertained by serial
imaging, clinical pathologic fractures, spinal cord compression,
and surgery or radiation therapy to bone. Reduction in the
frequency of SREs is an approvable end point in its own right, used
in several trials to support the approval of zoledronic acid and
denosumab.57,58 The registration study of radium-223 used a
composite bone end point, symptomatic skeletal events (SSEs),
deﬁned as symptomatic fracture, radiation or surgery to bone, or
spinal cord compression.9,59
PCWG3 advises reporting SSEs that include only symptomatic
events of clear clinical signiﬁcance, in contrast to SREs, which also
include asymptomatic fractures. The prospective evaluation of
composite end points such as SSEs that incorporate rPFS and
clinical progression is warranted, to determine which end point
may be most associated with clinical beneﬁt and/or survival after
treatment with a speciﬁc agent class.
PROs
Control/Relieve/Eliminate
PCWG3 supports standardizing an approach for reliable and
quantitative assessment of the patient experience in prostate cancer
trials. PCWG3 reafﬁrms that demonstrating pain palliation requires
a patient population with clinically meaningful pain at baseline
(eg,$ 4 on a 10-point pain intensity scale) and a response deﬁned as
a clinically meaningful score improvement at a subsequent time
point (eg, a 30% relative or 2-point absolute improvement from
baseline at 12 weeks, conﬁrmed at least 2 weeks later, without an
overall increase in opiate use).34 Serial (eg, daily) assessments at each
time point can improve the stability of values. These principles may
be extended to any patient-reported disease-related symptom end
point for which a clinically meaningful baseline score has been
determined, together with a responder deﬁnition that is based on a
sustained clinically meaningful score improvement.60 Physical
functioning should be assessed serially using a validated instrument
(eg, EORTC QLQ-C30 or PROMIS).
Delay/Prevent
For a time-to-pain-progression analysis, patients with any level
of baseline pain are eligible. Those without pain are followed for
development of pain, whereas those with baseline pain are followed for
pain progression (eg, a 2-point increase without an overall decrease in
opiate use). A pain assessment should be administered at treatment
discontinuation and once again if feasible (eg, 2 to 4 weeks later).
When product labels are correct, they should include time-to-pain-
progression end points, such as the time to development of opiate-
dependent pain.61 Time to deterioration of physical function should
also be included, with a priori thresholds deﬁning clinically meaningful
deterioration score changes.
Table 4. Suggested Frequency of Assessment for Commonly Used Measures in Metastatic Prostate Cancer Clinical Trials
Measure* PCWG2 Frequency (2008) PCWG3 Frequency (2015)†
Clinical
Symptoms/ performance status Every cycle Retained
Blood-based markers
PSA By cycle (every 3 or 4 weeks) Retained
ALK, LDH By cycle (every 3 or 4 weeks) Retained
Serum chemistry, CBC Not addressed By cycle (every 3 to 4 weeks)
Circulating tumor cells Not addressed By cycle (every 3 to 4 weeks) if available
Imaging
Bone scans Every 12 weeks Every 8 to 9 weeks for ﬁrst 24 weeks, then every 12 weeks†
CT/MRI Every 12 weeks Every 8 to 9 weeks for ﬁrst 24 weeks, then every 12 weeks†
Patient-reported outcomes Not addressed By cycle (every 3 to 4 weeks)
Analgesic consumption (opioids/no opioids) Not addressed By cycle (every 3 to 4 weeks)
Abbreviations: ALK, alkaline phosphatase; CT, computed tomography; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; PCWG2, Prostate Cancer
Clinical Trials Working Group 2; PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-speciﬁc antigen.
*All measures should be assessed at baseline to determine changes over time.
†Theremay be exceptions to these suggestions: in nonmetastatic castration-resistant prostate cancer trials, for example, imaging assessment intervals of 16weeks are
advised. Likewise, in long-term responders (. 2 to 3 years of clinical beneﬁt and no signs of clinical or biomarker progression), reduced frequency of imaging is
reasonable, such as every 16 to 24 weeks (4 to 6 months).
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Description of Adverse Events
Collection of patient-reported symptoms related to adverse
events from treatment should be considered using the National
Cancer Institute’s PRO-CTCAE.36 Inclusion of PRO-CTCAE
should be considered in both early- and late-phase clinical tri-
als. Results from PRO-CTCAE analyses can help determine
optimal dosing and tolerability and can inform the risk:beneﬁt
evaluation of treatments.
PROGRESSION FROM nmCRPC TO mCRPC
Lymph Nodes
PCWG3 recommends that lymph nodes that were previously
normal in size (, 1.0 cm) or pathologic in sizemust have grown by at
least 5mm in the short axis frombaseline or nadir and be$ 1.0 cm in
the short axis to be considered to have progressed. If the node
progresses to $ 1.5 cm in the short axis, it is pathologic and
measurable. Nodes that have progressed to between 1.0 and less than
1.5 cm are pathologic subject to clinical discretion and are non-
measurable. These guidelines apply to studies involving patients with
both metastatic and nonmetastatic disease. For existing pathologic
adenopathy, progression is deﬁned per RECIST 1.1.
Visceral
The date of ﬁrst metastasis is the date on which an unequivocal
visceral lesion by RECIST 1.1 is determined. No conﬁrmatory scan is
required unless the protocol uses modiﬁed criteria for immuno-
therapy.62 Visceral disease should be reported as being with or
without other patterns of spread (node, bone).
Bone
Documentation of radiographic evidence of metastatic disease
should include the time of the unequivocal development of new
sites on bone scintigraphy. Given the earlier disease setting, it is
advised that the scanning interval be increased to 16 weeks rather
than the 8 weeks recommended for trials in mCRPC (Table 4).
With 8-week intervals, it is less clear whether the detection of new
sites of disease on a ﬁrst follow-up bone scan represents ﬂare of a
pre-existing subclinical metastatic lesion(s) or a true transition
from a nonmetastatic to a metastatic state.
In such cases, PCWG3 advises that the event be recorded, and
that both the treatment and serial radiographic assessments be
continued until two additional new lesions are detected, assuming
the treatment is being tolerated well and there is no clinical reason
to discontinue it. Both the date of the initial detection of metastatic
disease and the date of subsequent progression should be recorded
and both intervals, metastasis-free survival (MFS) and rPFS, should
be reported. Because the optimal method to conﬁrm new metastatic
bone disease is uncertain at this time, the deﬁnition ofMFS should be
discussed with regulatory authorities if the MFS end point is being
considered for a trial intended to support drug approval.
Use of Confirmatory Scans With Other Modalities
For patients who develop equivocal bone lesions while on
study, PCWG3 discourages the use of other scanning modalities,
including MRI, positron emission tomography, or other inves-
tigational scans that were not used to determine eligibility for the
study. Supplemental scanning using imaging modalities with
varied sensitivity that were selected by personal preference or
regional practice may introduce bias.
MIXED RESPONSES
Individual metastatic foci in a particular site of disease or in
the patient as a whole may be biologically distinct. Such biologic
heterogeneity can result in a mixed response to treatment, wherein
one site responds favorably and another unfavorably. This phe-
nomenon has been considered historically as disease progression
that requires a change in therapy. PCWG3 advises focusing on the
entirety of disease rather than on a subset of index lesions. A review
of the disease as a whole using each modality used at baseline is
recommended. Biopsies of these growing, nonresponding, and
new lesions may provide insights into mechanisms associated with
resistance.
Control/Relieve/Eliminate
Whether favorable changes are occurring in all lesions in an
organ or disease site, or in a subset of lesions, should be reported;
whether they are occurring in one organ site or across sites of
involvement should be reported separately.
Baseline
Post
= New Bone Lesions
Two new lesions
at week 9
(new baseline)
No progression at
week 17 or at week
25 (2+2 rule not met)
Progression is at week 37 (two new lesions
relative to week 9; these lesions are
confirmed at week 49)= Stable Lesions
Week 9 Week 17 Week 37 Week 49
Fig 2. Controlling for ﬂare by applying the
212 rule using the ﬁrst post-treatment scan
as baseline.
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Delay/Prevent
Progression may not occur in all sites. PCWG3 encourages
reporting whether worsening represents the growth of one to two
existing foci in an organ or disease site, or the development of new
lesions in an organ or disease site that was previously uninvolved.
NLCB: PROGRESSION VERSUS THE DECISION TO
DISCONTINUE THERAPY
PCWG2 encouraged the continuation of treatment if a rising
PSA or worsening of an isolated disease site that was not clinically
signiﬁcant was the sole indicator of disease progression and the
patient was otherwise tolerating therapy. Now, recognizing the
biologic heterogeneity of individualmetastatic lesions, PCWG3draws
the distinction between documenting progression for consistency of
reporting (eg, recording the date of documented progression in a site
of disease such as a lymph node that is unlikely to adversely affect
prognosis) versus the decision to stop therapy.
To address this, PCWG3 introduces the no longer clinically
beneﬁting (NLCB) reporting metric deﬁned as the date and the
speciﬁc reason(s) a therapy was ultimately discontinued. This end
point permits individualized provider-patient decisions to con-
tinue or discontinue a treatment based on the primary therapeutic
objective for which it is being administered and assessed, be
it quality of life, PROs, or survival. As an example, in cases in
which multiple sites of disease continue to respond but one to
two sites grow, focal therapy such as radiation or surgery could be
administered to the resistant site(s) and systemic therapy con-
tinued. Similarly, therapy may be continued if progression by PSA
or imaging is slow and the disease-related symptoms that were
present at baseline remain controlled. Important here is to record
in detail the speciﬁc reasons why a therapy was ultimately dis-
continued, which may include clinical deterioration (clarifying
whether it is disease or therapy related) or need for a change in
systemic therapy. PCWG3 cannot deﬁne the risks/beneﬁts at the
individual level for continuation of therapy beyond progression, but
sets the goal of prospectively deﬁning the circumstances in which
scenarios are identiﬁed where continuing a therapy is justiﬁed.
Clinical trials evaluating whether therapy A should be stopped and a
new one started, continued alone, or continued with a new one
added, are ongoing.
To illustrate the concept of NLCB, we recommend use of a
swimmers plot (Fig 3), in which each lane documents the indi-
vidual patient experience on a trial over time. This plot includes
signiﬁcant adverse events encountered, treatment discontinua-
tions, and the points at which the criteria for progression by a
speciﬁc disease manifestation were met while treatment was
continued up through the time treatment was ultimately dis-
continued. The information in each swim lane can also be used to
record the dates a focal therapy (eg, external beam radiation) was
used to treat nonresponding sites in cases in which multiple other
sites of disease are still responding. In both cases, the patient may
still be beneﬁting overall from a treatment, justifying its con-
tinuation. These plots are suggested for phase I and II studies and
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may be particularly useful in trials designed to assess the patient
experience across treatment groups.
SUMMARY
PCWG3 seeks to move the drug development process closer to
common clinical scenarios encountered in routine practice. It also
aims to allow a more complete characterization of the host and his
disease, not only at the start of therapy, but also over time as it
evolves under treatment, which may help establish the value and
the beneﬁt of continuing a therapy when there are signs that the
disease is beginning to progress.
PCWG3 emphasizes the distinction between adenocarci-
nomas and other histologies, moves away from the pre- and
post-taxane categorization, and recommends eligibility on the
basis of prior therapies received. This should result in a greater
focus on developing speciﬁc protocols for the distinct clinical
phenotypes. An important addition to PCWG3 is the recom-
mendation to describe the percentage of patients with a speciﬁc
disease pattern; in some cases, stratiﬁcation for a speciﬁc
pattern of disease may be indicated. Focusing PROs on core
concepts of disease-related symptoms, physical functioning,
and adverse events of therapy is advised, with the goal of
improving the standardization of PRO in prostate cancer
clinical trials.
Serial biologic proﬁling of the disease before treatment,
while receiving treatment, and at progression is also advised. To
establish clinical signiﬁcance, PCWG3 advises evaluating the
strength of the association between early changes in individual
outcome measures, be they clinical, biochemical, PROs, imaging,
CTCs, or other molecular determinants, and later events such as
rPFS or clinical progression-free survival and/or overall survival.
Standards for the interpretation of outcomes for therapies that
affect the immune system are also needed. Although improve-
ments in symptoms and/or functional status can be clinical
beneﬁts in their own right, determining the clinical signiﬁcance
of a statistically signiﬁcant change in a PRO measure is another
area of focus. Finally, PCWG3 underscores the distinction
between the need to consistently report progression by indi-
vidual disease manifestation in the order in which they occur (be
it PSA, imaging, or other surrogate) from the need to terminate a
treatment because the patient is NLCB from the therapy he is
currently receiving.
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Appendix
The Dual-Objective Framework for Therapeutic Objectives
The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) retains the dual-objective structure described by the Prostate
Cancer Clinical Trials Working Group 2 (PCWG2), categorizing therapeutic objectives as control/relieve/eliminate versus delay/
prevent. Delay/prevent objectives include manifestations that are clinically signiﬁcant trial end points in their own right, such as
symptomatic skeletal events or prolonged survival. This model aligns with the indications and uses of the currently approved drugs
(see Appendix Table A1). Notable is that pain is the only control/relieve/eliminate end point for which therapies are approved or
indicated.
The Biomarker Context of PCWG3
Drug development programs are designed to demonstrate clinical beneﬁt with acceptable safety in well-controlled studies.63
Optimally, the clinical beneﬁt should fulﬁll an unmet need. PCWG3 considers all aspects of the clinical trial process within a
biomarker context, from discovery or deﬁnition, to analytical assay validation, to clinical validation.64,65 The biomarker may be a
clinical measure (eg, functional status), patient-reported outcome, tumor or host biochemical measure, imaging parameter, or
molecular determinant. PCWG3 encourages deﬁning and evaluating biomarkers for speciﬁc contexts of use during the early phases
of drug development to enable validation in later-phase trials. The demonstration of a biomarker’s clinical usefulness (which shows
that the risk/beneﬁt outcome for the patient is improved when the biomarker test result is used in making the therapeutic decision)
is also emphasized.66
Calculating Prostate-Specific Antigen Doubling Time
Prostate-speciﬁc antigen (PSA) doubling time should be calculated using a linear regression model of the normal logarithm of
PSA and time.67 The calculation should be based on (1) at least three consecutive PSA values with each value $ 0.2 ng/dL, (2)
inclusion of the most recent PSAvalues during androgen deprivation therapy, and (3) interval between ﬁrst and last PSAvalues of$
8 weeks but # 12 months.20,21,67
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Table A1. Indications and Regulatory Labels for the Currently Approved Drugs for CRPC, Aligned With the PCWG3 Manifestation-Speciﬁc Outcome Framework
Early manifestations (response): control, relieve, or eliminate
Approved to control pain or indicated for patients with symptoms
Mitoxantrone plus prednisone for the treatment of patients with pain related to advanced hormone-refractory prostate cancer
89Sr for the relief of bone pain in patients with painful skeletal metastases
153Sm for relief of pain in patients with osteoblastic metastatic bone lesions that enhance on radionuclide bone scan
Radium-223* (symptoms from bone metastases with no involvement of other organs)
No FDA drug approvals on the basis of:
PSA declines
Tumor shrinkage
Bone scan improvement
Changes in circulating tumor cell number
Later manifestations (progression): delay or prevent
Approved or shown to delay SREs or SSEs
Zoledronic acid (SRE)
Denosumab (SRE)
Abiraterone acetate (SRE)*,†
Enzalutamide (SRE)*,†
Radium-223 (SSE)*,‡
Approved for delay of death (survival)
Docetaxel
Sipuleucel-T
Cabazitaxel
Abiraterone acetate plus prednisone
Enzalutamide
Radium-223
Delay of radiographic progression using PCWG2-based criteria, coprimary with survival
Abiraterone acetate plus prednisone
Enzalutamide
Abbreviations: CRPC, castration-resistant prostate cancer; FDA, United States Food & Drug Administration; PCWG2, Prostate Cancer Clinical Trials Working Group 2;
PCWG3, Prostate Cancer Clinical Trials Working Group 3; PSA, prostate-speciﬁc antigen; SREs, skeletal-related events; SSEs, symptomatic skeletal events.
*Indicated for patients with symptoms.
†Shown to delay SREs.
‡Shown to delay SSEs.
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Fig A1. Three patterns of biomarker (eg, PSA) response to agents that effect cell kill. Shown are a substantial and durable decline consistent with marked sensitivity (gray
line); a decline followed by a slow rise, indicative of partial sensitivity followed by acquired resistance (gold line); and a transient drop (or none at all) followed by an
immediate rise, consistent with either de novo or intrinsic resistance (blue line). PSA, prostate-speciﬁc antigen.
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POSTERIOR
NaF PETTc-99 MDP FDG PET
TB BONE SCAN
ANTERIOR
Fig A2. Radionuclide bone scan, sodium ﬂuoride PET scan, and FDG PET scan of the same patient. Only FDG PET is tumor directed; Tc-99 MDP and NaF PET are bone
directed. Note that neither the target of the tracer nor the clarity of the image necessarily implies a superior biomarker, and eachmodality must be validated analytically and
clinically. 99mTc MDP, 99mTc methylene diphosphonate; NaF, sodium ﬂuoride; FDG, ﬂuorodeoxyglucose; PET, positron emission tomography.
Fig A3. Bone scan assessment form.
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Fig A3. (Continued).
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Fig A3. (Continued).
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